In our retrospective cohort of 129 NSCLC patients, the frequencies of BRCA1/2 and HR mutations were 13.2% (17 of 129) and 29.5% (38 of 129), while the frequencies of deleterious BRCA1/2 and HR mutations were 8.5% (11 of 129) and 29.5% (38 of 129), respectively, suggesting that approximately 30% of patients with advanced NSCLC may benefit from chemotherapy. Here, BRCA1 is linked to non-small cell lung carcinoma.